| 产品描述: | Liarozole (R75251; R85246) is an imidazole derivative and orally active retinoic acid (RA) metabolism-blocking agent (RAMBA). Liarozole inhibits the cytochrome P450 (CYP26)-dependent 4-hydroxylation of retinoic acid (IC50=7 μM), resulting in increased tissue levels of retinoic acid. Liarozole shows antitumoral properties |
| 靶点: |
CYP26:7 μM (IC50) |
| 体外研究: |
Liarozole (0.01~10 μM; 9 days; MCF-7 cells) inhibits cells proliferation.
Liarozole (1 μM; 4 days; mesenchymal cells) completely inhibits chondrogenesis. |
| 体内研究: |
Liarozole (5-20 mg/kg; p.o.; 3 days) reverses the vaginal keratosis caused by estrogen stimulation. Liarozole (40 mg/kg; p.o.; 21 days) reduces tumor burden substantially. Animal Model: Ovariectomized rats Dosage: 5~20 mg/kg Administration: P.o.; 3 days Result: Reversed the vaginal keratosis caused by estrogen stimulation. Animal Model: SCID mice Dosage: 40 mg/kg Administration: P.o.; 21 daysResult: Inhibited tumor growth and survival. |
| 参考文献: |
1. Kuijpers AL, et al. The effects of oral liarozole on epidermal proliferation and differentiation in severe plaque psoriasis are comparable with those of acitretin. Br J Dermatol. 1998;139(3):380-389.
2. Lucker GP, et al. Oral treatment of ichthyosis by the cytochrome P-450 inhibitor liarozole. Br J Dermatol. 1997;136(1):71-75.
3. Wouters W, et al. Effects of liarozole, a new antitumoral compound, on retinoic acid-induced inhibition of cell growth and on retinoic acid metabolism in MCF-7 human breast cancer cells. Cancer Res. 1992;52(10):2841-2846.
4. Pignatello MA, et al. Liarozole markedly increases all trans-retinoic acid toxicity in mouse limb bud cell cultures: a model to explain the potency of the aromatic retinoid (E)-4-[2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthylenyl)-1-propenyl] benzoic acid. Toxicol Appl Pharmacol. 2002; 178(3):186-194.
5. Van Wauwe J, et al. Liarozole, an inhibitor of retinoic acid metabolism, exerts retinoid-mimetic effects in vivo. J Pharmacol Exp Ther. 1992;261(2):773-779.
6. Stearns ME, et al. Liarozole and 13-cis-retinoic acid anti-prostatic tumor activity [published correction appears in Cancer Res 1993 Dec 1;53(23):5831]. Cancer Res. 1993;53(13):3073-3077. |
| 溶解性: |
Soluble in DMSO |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 备注: |
Liarozole (R75251; R85246) 是一种咪唑衍生物和具有口服活性的维甲酸 (RA) 代谢阻断剂 (RAMBA)。Liarozole 抑制维甲酸依赖的细胞色素 P450 (CYP26) 4- 羟基化 (IC50=7 μM),导致组织维甲酸水平增加。Liarozole 具有抗肿瘤特性。 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
3.239 ml |
16.194 ml |
32.388 ml |
| 5 mM |
0.648 ml |
3.239 ml |
6.478 ml |
| 10 mM |
0.324 ml |
1.619 ml |
3.239 ml |
| 50 mM |
0.065 ml |
0.324 ml |
0.648 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |